Inova Joins PierianDx Partner Network to Provide Precision Medicine to Cancer Patients
by Josh Forsythe, on February 19, 2015
ST LOUIS, MO and FALLS CHURCH, VA – PierianDx announced today that the Inova Translational Medicine Institute has joined the network of leading academic medical centers and hospital systems using PierianDx’s genetic testing software and services.
PierianDx offers a robust informatics software solution that efficiently manages next-generation sequencing processes and shares comprehensive clinical insights on gene panels. By providing an efficient workflow solution and deep and easily accessible knowledgebase, PierianDx enables its partners to provide more personalized patient diagnosis and ultimately more effective outcomes.
Inova Translational Medicine Institute is working with PierianDx to provide more personalized diagnosis to its cancer patients. Inova is using PierianDx’s platform to classify, interpret and report on genes in the Life AmpliSeq Tumor assay.
“The Inova Translational Medicine Institute is excited to team with PierianDx to deliver on the potential of personalized medicine,” according to John Niederhuber, MD, CEO of ITMI. “The knowledgebase, interpretation, and reporting solution provided by PierianDx will allow our medical professionals to seamlessly link the genetic profile of each of our patients to known therapies and trials.”
PierianDx enables clinical labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In use since 2011, and constantly growing with new patient and clinical and research data, PierianDx’s proprietary Clinical Genomicist Workstation software, knowledgebases, IT backbone and workflow management tools provide clinical labs everything they need to manage their next-generation sequencing processes. For more information, please visit www.pieriandx.com or @PierianDx on Twitter.
About Inova Translational Medicine Institute
The Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute delving into the genomics component of personalized medicine. ITMI is utilizing genomic and clinical information from patients to develop innovative methods for personalized patient care. Pilot studies at the Institute have generated a large genomic and clinical data set that can be used as pilot data in a variety of fields, from computational biology to psychology as well as more obvious biomedical research applications. ITMI’s goal is to utilize information from its pilot studies to better understand and predict the onset of disease, leading to the implementation of preventive medicine based on the unique genomics of the individual patient.